The business plan.

The TP53/P53 pathway is mutated in most malignancies.  This means that a protein is misfolded, or not being translated correctly.  It can be caused by many different factors such as oxygen radicals, genetics, viral infection, etc.  This pathway is necessary for programmed apoptosis. 

Caskee Industries has each protein of the entire cascade derived into plasmids in order to be knocked in, stably, in order to replace the mutated proteins.  The effector proteins number 27.  The core regulator genes number at 2.  The mediator genes numbered at 4.

We choose stable knock in so the daughter cells will to continue the correct genotype in order to be the phenotype necessary.

We can theoretically correct a cell by transfecting the malignant tissue. 

Caskee Industries is a ground breaking research and development company.  We focus on genetics, methods, and protocols for infectious disease and malignancy.

A glioma is the most common form of brain cancer.  Glioblastoma is the most common Glioma.

Caskee Industries also has an exhaustive collection of CRISPR knock down plasmids for CCR5 and CXCR4, the two attachment proteins of HIV.  Along with the methods and protocols necessary.

We also have history of vaccine inventing.

Most malignancy has a mutated TP53/P53 pathway.  We have knock in plasmids designed for each of the cascade proteins.  This makes the  variable the tissue to be transfected.

At Caskee Industries we design methods and protocols for protein knock in and protein knock out plasmids stuffed inside a vector or naked DNA or naked RNA to be transfected to the malignant, or infected cell to be edited such as the Astrocytoma or the Hematopoietic Stem Cell.

These genes become transgenes and are stably transfected and replace the mutated gene in order to replace the structurally perverted gene product.

These plasmids are used in cancer therapy research and infectious disease.

At Caskee Industries we also design the necessary genetics, methods, and protocols for state of the art vaccines.

Caskee Industries has knock in plasmids to knock in mutated proteins for the entire TP53/P53 pathway.  Including the effector proteins numbered at 27.  The core regulator genes numbered at 2.  The mediator genes numbered at 4.  The genes are designed to be knocked in using the lastest imaging software and surgeon.  The TP53/P53 is array in most cancer which makes the different between malignances the actual tissue to be transfected.

We have an exhaustive list of CRISPR Cas 9 knock out plasmids for the two chemokine receptor protein expressed on the T-cell, to be transfected into Hematopoietic Stem Cell.

Our gene therapies theoretically,  aim to correct genetic defects by delivering therapeutic genes to the affected cells, potentially curing a wide range of genetic diseases and malignancies.  

My customer will be the doctor that prescribes the medicine.  The affected person is a customer as well.

We work on developing innovative drug delivery systems that improve the efficacy and safety of drugs. Our team of experts uses advanced materials and techniques to create delivery systems that can target specific cells or tissues, and release drugs over a longer period of time.

In order to continue my research I need funding for a BSL1 laboratory fully equipped in a dome.

My time. 

Our gene editing technology allows us to precisely and efficiently modify genomic sequences, opening up a new world of possibilities for disease treatment and agricultural advancement.

To our customers there will be direct mailings. Such as oncology seminars and infectious disease seminars.

Sales will be made through the drug wholesaler.